BioIndustry Association Release: "Med City" Investment Demonstrates Mayor's Commitment to Life Sciences

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

24 July 2013 -- Commenting on the announcement today by the Mayor of London that the London Enterprise Panel will provide a grant to establish 'Med City' in London, Steve Bates, BioIndustry Association (BIA) Chief Executive Officer, said:

"The BIA welcomes the establishment of 'Med City' which I believe could be a powerful tool to support life sciences innovation in the UK. I applaud the commitment shown to the sector by the Mayor, Boris Johnson, and his deputy, Kit Malthouse, and look forward to working with them to further this initiative.

"The goal for 'Med City' is closely aligned with that of the BIA: to encourage investment into life sciences and to ensure that scientific advances are exploited to deliver healthcare benefits to patients and to boost the UK economy."

For further information, please contact Robert Winder, Head of Communications, rwinder@bioindustry.org, 020 7630 2191; mobile 07825 942 934.

BioIndustry Association

Founded over 20 years ago at the infancy of biotechnology, the BioIndustry Association (BIA) is the trade association for innovative enterprises involved in UK bioscience. Members include emerging and more established bioscience companies; pharmaceutical companies; academic, research and philanthropic organisations; and service providers to the bioscience sector. The BIA represents the interests of its members to a broad section of stakeholders, from government and regulators to patient groups and the media. Our goal is to secure the UK's position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people's lives. For further information, please go to www.bioindustry.org

Help employers find you! Check out all the jobs and post your resume.

Back to news